Claudiana Lameu
Sao Paulo, SP, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.
Journal: Molecular neurobiology
Published: February 06, 2026
Purinergic signaling in health: special issue of purines 2022 in Brazil.
Journal: Purinergic signalling
Published: January 20, 2025
Effects of nanoflubendazole and purinergic signaling modulation in overcoming neuroblastoma chemoresistance.
Journal: Purinergic signalling
Published: September 27, 2024
P2X7 receptor in macrophage polarization and its implications in neuroblastoma tumor behavior.
Journal: Purinergic signalling
Published: July 03, 2024
Impairment of adenosine signaling disrupts early embryo development: unveiling the underlying mechanisms.
Journal: Frontiers in pharmacology
Published: October 26, 2023
Optimizing adjuvant inhaled chemotherapy: Synergistic enhancement in paclitaxel cytotoxicity by flubendazole nanocrystals in a cycle model approach.
Journal: International journal of pharmaceutics
Published: July 15, 2023
Bj-PRO-10c, as an allosteric regulator of argininosuccinate synthase, is a potential therapy for neuroblastoma metastasis.
Journal: Toxicon : official journal of the International Society on Toxinology
Published: May 09, 2023
Eicosapentaenoic acid-rich oil supplementation activates PPAR-γ and delays skin wound healing in type 1 diabetic mice.
Journal: Frontiers in immunology
Published: January 10, 2023
Purinergic signaling in cognitive impairment and neuropsychiatric symptoms of Alzheimer's disease.
Journal: Neuropharmacology
Published: October 20, 2022
P2X7 receptor isoform B is a key drug resistance mediator for neuroblastoma.
Journal: Frontiers in oncology
Published: June 10, 2022
Cancer Metabostemness and Metabolic Reprogramming via P2X7 Receptor.
Journal: Cells
Published: May 18, 2021
Last Updated: 09/26/2026